Vestmark Advisory Solutions Inc. Sells 33,131 Shares of Boston Scientific Corporation $BSX

Vestmark Advisory Solutions Inc. trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 42.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 45,526 shares of the medical equipment provider’s stock after selling 33,131 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Boston Scientific were worth $4,890,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. GAMMA Investing LLC increased its stake in shares of Boston Scientific by 15.4% in the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after purchasing an additional 3,932 shares in the last quarter. MRA Advisory Group purchased a new position in shares of Boston Scientific during the 2nd quarter valued at $273,000. Bank of New Hampshire boosted its holdings in Boston Scientific by 552.0% in the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after buying an additional 16,699 shares during the period. NS Partners Ltd raised its holdings in Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after acquiring an additional 5,704 shares during the period. Finally, New England Research & Management Inc. purchased a new position in shares of Boston Scientific in the second quarter valued at about $1,133,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 1.0%

BSX stock opened at $100.05 on Friday. The firm’s fifty day simple moving average is $100.09 and its two-hundred day simple moving average is $102.45. The stock has a market capitalization of $148.26 billion, a price-to-earnings ratio of 53.50, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the company posted $0.63 EPS. The firm’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 175,782 shares of company stock valued at $17,742,314. Corporate insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on BSX. UBS Group increased their price objective on shares of Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Royal Bank Of Canada restated an “outperform” rating and set a $125.00 price objective on shares of Boston Scientific in a research report on Monday, September 29th. Wells Fargo & Company boosted their target price on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Morgan Stanley increased their price target on Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Finally, Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.